Based on the high response rates of patients with PD-L1-positive tumors, a high level of PD-L1 expression within a tumor was the first FDA approved predictive biomarker for the selection of patients who were likely to respond to anti-PD-1/PD-L1 immunotherapies 12, 13. The gene discussed is PDCD1; the disease is neoplasm.